Immune response to a malignant tumor is a known indicator in predicting patient response to therapy. Historically, tumor immune response has been characterized using immunohistochemistry, but, more recently, gene expression profiling based on next-generation sequencing has emerged as an alternative to classify a tumor’s inflammation status.
This white paper describes the development and verification of three new oncology signatures for classifying a tumor’s inflammation status: the HTG EdgeSeq Reveal Immune, Stroma, and Tumor Microenvironment signatures. These signatures are built upon the HTG EdgeSeq research use only Precision ImmunoOncology Panel. The data presented demonstrate that the HTG EdgeSeq Immune, Stroma, and TME scores offer an accurate and robust method for determining the inflammation and stroma status of tumor FFPE samples.
Offered Free by: HTG Molecular Diagnostics
See All Resources from: HTG Molecular Diagnostics